Medicare beneficiaries who qualify for discounted GLP-1 weight-loss medications now face a hard deadline. The Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge on July 1, 2026, allowing eligible Part D enrollees to fill certain GLP-1 prescriptions for a flat $50 monthly copay. That price, however, expires on December 31, 2027, giving patients just 18 months of access before the demonstration ends and standard pricing returns.
How the $50 GLP-1 copay works and why the 2027 deadline matters
The Medicare GLP-1 Bridge is structured as a short-term payment demonstration, not a permanent benefit. CMS designed it to run from July 1, 2026, through December 31, 2027, and it operates entirely outside the normal Part D accounting system. That means prescriptions filled under the Bridge do not accumulate toward a beneficiary’s Part D out-of-pocket spending thresholds, according to CMS guidance for Part D plans. The program uses the existing LI NET infrastructure, with Humana serving as the central processor for claims.
For manufacturers participating in the Bridge, the agreed-upon net price is $245 per monthly supply. Beneficiaries pay $50 at the pharmacy counter, and the federal government covers the difference. That $245 figure represents a steep discount from the retail cost of branded GLP-1 drugs, which can run well above $1,000 per month without insurance. The gap between $50 and $245 is where the financial tension sits: manufacturers accept a lower net price in exchange for volume, while the government absorbs the subsidy cost for a fixed window.
The 18-month clock creates a specific problem for patients who start treatment in mid-2026 or later. GLP-1 medications for weight loss are typically prescribed as ongoing therapy, not short courses. A beneficiary who begins filling prescriptions in July 2026 will have access to the $50 rate for a year and a half, then face a return to whatever price their Part D plan negotiates independently. CMS has published no official guidance on what happens to patients mid-treatment when the Bridge expires, leaving prescribers to weigh the risk of starting a therapy that may become unaffordable on January 1, 2028.
The Bridge also interacts awkwardly with Medicare’s broader rules on weight-loss drugs. Under longstanding policy, Medicare generally does not cover medications “used for anorexia, weight loss, or weight gain,” a position outlined on the official Medicare coverage page. The GLP-1 Bridge carves out a temporary exception for selected products and indications, but it does not rewrite the underlying statute. That legal backdrop reinforces the program’s temporary nature and the uncertainty surrounding coverage once the demonstration ends.
The $245 net price and its pressure on drugmakers after 2027
CMS has framed the Bridge explicitly as an interim step toward a larger initiative called the BALANCE model, according to the agency’s innovation office, which described the demonstration as a bridge to longer-term affordability strategies in its innovation insight. That framing signals the government expects a more durable pricing structure to replace the demonstration, but no finalized BALANCE timeline or pricing terms have been published.
The $245 manufacturer net price establishes a reference point that will be difficult to walk back. Once thousands of Medicare enrollees fill prescriptions at that rate, any post-2027 price increase will be visible and politically charged. Drugmakers that participated in the Bridge will face pressure to offer comparable concessions in whatever replaces it, whether through the BALANCE model, direct Part D negotiations, or future legislation. Walking away from the Medicare market after 18 months of volume would mean ceding share to competitors willing to keep prices closer to the Bridge level.
CMS has been explicit that the Bridge is meant to expand near-term access while testing operational details, a point underscored in the agency’s press release announcing the launch. By locking in a defined net price and standardized copay, the demonstration gives policymakers data on utilization, adherence, and budget impact at a specific price point. Those data will shape future negotiations with manufacturers, who will have to justify any higher net prices against real-world experience from the Bridge period.
At the same time, the program’s off-books structure-operating outside standard Part D benefit phases-limits how much it can be scaled or extended without congressional action. Because Bridge claims do not count toward out-of-pocket thresholds, beneficiaries who rely on GLP-1s during the demonstration may see a sudden shift in their Part D spending pattern once the program ends. In 2028, the same prescription could both cost more at the counter and begin counting toward catastrophic coverage, reshaping annual drug budgets for affected patients.
For now, the clearest takeaway is timing. Patients who qualify and start therapy early in the demonstration will maximize their months at the $50 copay, but they and their clinicians must plan for a potential cliff when the calendar turns to 2028. Manufacturers, meanwhile, are effectively on notice that $245 per month has become a public benchmark for Medicare GLP-1 pricing. Whatever comes after the Bridge-whether the BALANCE model, new legislation, or a patchwork of Part D negotiations-will unfold in the shadow of that number and the expectations it has created.
Free tool for readers: Not sure whether your own retirement is on track? You can check your free Retirement Safety Score — a 0–100 number plus a few personalized steps — in about five minutes, with no sign-up required to see your score.
